Cellenkos

Cellenkos® was founded in 2016 with the licensing of a proprietary umbilical cord blood T-Regulatory (Tregs) cell therapy platform from MD Anderson Cancer Center and funded by Golden Meditech Holdings Ltd, a Hong Kong-based integrated healthcare enterprise. Being derived from umbilical cord blood, cellenkos’ Tregs are naïve, bonafide suppressor cells that resolve inflammation through multiple direct and indirect interactions. Cellenkos is dedicated to the development and commercialization of the allogeneic, off-the-shelf cell based products for the treatment of various inflammatory diseases and autoimmune disorders, in diverse therapy areas.